Provided by Tiger Trade Technology Pte. Ltd.

Eledon Pharmaceuticals, Inc.

2.19
+0.220011.17%
Post-market: 2.16-0.0316-1.44%19:06 EST
Volume:738.12K
Turnover:1.58M
Market Cap:164.33M
PE:-2.00
High:2.20
Open:1.98
Low:1.98
Close:1.97
52wk High:4.97
52wk Low:1.35
Shares:75.03M
Float Shares:74.99M
Volume Ratio:1.46
T/O Rate:0.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0976
EPS(LYR):-0.7454
ROE:-95.49%
ROA:-44.22%
PB:1.80
PE(LYR):-2.94

Loading ...

Eledon Pharmaceuticals Reports Positive 24-Month Phase 1b Data for Tegoprubart in Kidney Transplant Patients

Reuters
·
Jan 26

Analysts Conflicted on These Healthcare Names: Ufp Technologies (UFPT), Eledon Pharmaceuticals (ELDN) and CareDx (CDNA)

TIPRANKS
·
Jan 23

Eledon Pharmaceuticals Inc - Funds Expected to Support Operations Into 2Q 2027

THOMSON REUTERS
·
Jan 09

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook

GlobeNewswire
·
Jan 09

Eledon Pharmaceuticals Swaps Shares for Pre-Funded Warrants in Private Exchange

Reuters
·
Jan 03

Eledon Pharmaceuticals CEO to Join Fireside Chat at Piper Sandler Healthcare Conference

Reuters
·
Dec 01, 2025

Eledon Pharmaceuticals Shares Rise About 10% to $1.69 in Active Trading Volume After the Bell Following Preliminary Update on Drug Test in Diabetes Patients

THOMSON REUTERS
·
Nov 19, 2025

BRIEF-Eledon Reports Preliminary Data From First Six Patients With Type 1 Diabetes Treated With Tegoprubart As The Core Immunosuppressant

Reuters
·
Nov 19, 2025

Eledon Pharmaceuticals Reports Promising Early Results for Tegoprubart in Islet Transplant Trial for Type 1 Diabetes

Reuters
·
Nov 19, 2025

Eledon Reports Preliminary Data From First Six Patients With Type 1 Diabetes Treated With Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at Uchicago Medicine

THOMSON REUTERS
·
Nov 19, 2025

Eledon Pharmaceuticals Inc - Tegoprubart Well Tolerated, No Serious Infections or Rejection Events

THOMSON REUTERS
·
Nov 19, 2025

Eledon Pharmaceuticals Is Maintained at Buy by Guggenheim

Dow Jones
·
Nov 18, 2025

Eledon Pharmaceuticals price target lowered to $8 from $9 at Guggenheim

TIPRANKS
·
Nov 18, 2025

Eledon Pharma Q3 EPS $(0.21) Beats $(0.24) Estimate

Benzinga
·
Nov 15, 2025

Eledon Pharmaceuticals posts Q3 net loss of $17.5 million

Reuters
·
Nov 15, 2025

Eledon Pharmaceuticals Q3 Operating Expenses USD 19.07 Million

THOMSON REUTERS
·
Nov 15, 2025

Eledon Pharmaceuticals Q3 Income From Operations USD -19.07 Million

THOMSON REUTERS
·
Nov 15, 2025

Press Release: Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results

Dow Jones
·
Nov 15, 2025

Top News Today: Stocks Mixed as AI Selloff Slows

Dow Jones
·
Nov 15, 2025

Eledon Pharmaceuticals Shares Sink After Pricing $50M Public Offering

Dow Jones
·
Nov 12, 2025